GlaxoSmithKline’s (GSK) “Neutral” Rating Reaffirmed at Credit Suisse Group

Credit Suisse Group reissued their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a research note issued to investors on Thursday morning, ThisIsMoney.Co.Uk reports.

Other analysts have also issued research reports about the company. Barclays reaffirmed an equal weight rating on shares of GlaxoSmithKline in a report on Wednesday, April 10th. Deutsche Bank reaffirmed a hold rating and issued a GBX 1,520 ($19.86) target price on shares of GlaxoSmithKline in a report on Friday, April 5th. Shore Capital lowered GlaxoSmithKline to a hold rating in a report on Friday, January 18th. Jefferies Financial Group reaffirmed a buy rating on shares of GlaxoSmithKline in a report on Thursday, March 14th. Finally, UBS Group reaffirmed a neutral rating and issued a GBX 1,650 ($21.56) target price on shares of GlaxoSmithKline in a report on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company. GlaxoSmithKline currently has a consensus rating of Hold and an average price target of GBX 1,518.15 ($19.84).

GSK opened at GBX 1,568.40 ($20.49) on Thursday. The company has a market capitalization of $77.15 billion and a price-to-earnings ratio of 21.51. The company has a current ratio of 0.75, a quick ratio of 0.47 and a debt-to-equity ratio of 709.80. GlaxoSmithKline has a 12-month low of GBX 1,395.80 ($18.24) and a 12-month high of GBX 1,648.80 ($21.54).

The company also recently disclosed a dividend, which was paid on Thursday, April 11th. Stockholders of record on Thursday, February 21st were issued a dividend of GBX 23 ($0.30) per share. This represents a dividend yield of 1.49%. The ex-dividend date was Thursday, February 21st. This is a positive change from GlaxoSmithKline’s previous dividend of $19.00. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 1.26%.

In related news, insider Victoria Whyte purchased 3,020 shares of the firm’s stock in a transaction that occurred on Wednesday, February 13th. The shares were acquired at an average price of GBX 1,547 ($20.21) per share, with a total value of £46,719.40 ($61,047.17). Also, insider Jesse Goodman purchased 845 shares of the firm’s stock in a transaction that occurred on Wednesday, February 6th. The stock was bought at an average cost of GBX 1,964 ($25.66) per share, for a total transaction of £16,595.80 ($21,685.35). Insiders have bought a total of 3,873 shares of company stock worth $6,343,952 in the last three months.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also: What is Net Asset Value (NAV)?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.